- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/426 - 1,3-Thiazoles
Patent holdings for IPC class A61K 31/426
Total number of patents in this class: 3284
10-year publication summary
|
173
|
174
|
205
|
212
|
197
|
207
|
224
|
189
|
207
|
173
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 20172 |
43 |
| Genfit | 277 |
39 |
| Astellas Pharma Inc. | 1065 |
35 |
| Actelion Pharmaceuticals Ltd | 526 |
30 |
| Dompé Farmaceutici S.p.A. | 273 |
28 |
| EyePoint Pharmaceuticals, Inc. | 101 |
28 |
| Bristol-myers Squibb Company | 4845 |
25 |
| University of Florida Research Foundation, Inc. | 4060 |
24 |
| Purdue Research Foundation | 3691 |
24 |
| Romark Laboratories L.C. | 51 |
24 |
| Vanda Pharmaceuticals, Inc. | 367 |
24 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3369 |
22 |
| Takeda Pharmaceutical Company Limited | 2706 |
21 |
| Centre National de La Recherche Scientifique | 10611 |
20 |
| vTv Therapeutics LLC | 153 |
20 |
| Shionogi & Co., Ltd. | 842 |
19 |
| Teijin Pharma Limited | 261 |
19 |
| Duke University | 3095 |
18 |
| Cornell University | 3347 |
18 |
| Avexxin AS | 45 |
17 |
| Other owners | 2786 |